by 
Biopharma Clinical Trials Market Key Takeaways
- North America dominated the biopharma clinical trials market with the largest share of 49% in 2024.
- Asia Pacific is expected to grow at a significant CAGR from 2025 to 2034.
- By phase, the phase III segment contribute the biggest market share of 44% in 2024.
- By phase, the phase I segment is expected to grow at the fastest CAGR over the projected period.
- By therapeutic area, the oncology segment captured the highest market share of 34% in 2024.
- By therapeutic area, the rare/orphan diseases segment is anticipated to grow at a significant CAGR from 2025 to 2034.
- By molecule type, the monoclonal antibodies segment held the biggest market share of 29% in 2024.
- By molecule type, the cell & gene therapy segment is expected to expand at a significant CAGR from 2025 to 2034.
- By sponsor type, the big biopharma companies segment generated the major market share of 54% in 2024.
- By sponsor type, the emerging biotech segment is projected to grow at a significant CAGR between 2025 and 2034.
- By study design, the interventional trials segment accounted for the significate market share 64% in 2024.
- By study design, the decentralized/hybrid trials segment is likely to experience rapid growth in the market during the forecast period.
- By end user, the biopharmaceutical companies segment held the largest market share of 43% in 2024.
- By end user, the contract research organization (CRO) segment is expected to grow at a significant CAGR from 2025 to 2034.
- By service type, the patient recruitment and retention segment generated the highest market share of 21% in 2024.
- By service type, the eClinical solutions segment is expected to grow at a significant CAGR from 2025 to 2034.
How AI Is Transforming the Biopharma Clinical Trials Market
Artificial intelligence (AI) is significantly reshaping the biopharma clinical trials market by accelerating drug development, streamlining operations, and enhancing patient outcomes. By leveraging vast datasets, AI can predict drug efficacy, optimize trial protocols, and reduce the overall time and cost involved in bringing therapies to market. AI-powered tools improve patient recruitment by identifying ideal candidates based on real-world data and predictive modeling. They also enable real-time monitoring of clinical data, allowing early detection of adverse events and automated alerts to improve patient safety. Additionally, AI enhances trial design by simulating outcomes and refining inclusion criteria, ultimately leading to more targeted and successful clinical studies.
Market Overview
The biopharma clinical trials market includes the services, infrastructure, and technology platforms involved in planning, designing, executing, monitoring, and analyzing clinical trials for biopharmaceutical companies. These trials assess the safety, efficacy, and dosage of new biologics, biosimilars, gene therapies, cell therapies, vaccines, and combination therapies across various medical areas. The market consists of sponsors (biopharma companies), contract research organizations (CROs), site management organizations (SMOs), technology vendors, and analytics companies working through phases I–IV, in compliance with regulatory agencies like the FDA, EMA, PMDA, and NMPA. These trials are vital for advancing medical knowledge, creating new treatments, and securing regulatory approval. The market is growing due to an increasing number of chronic diseases, rising R&D investments, and the development of new therapies.
Drivers
Increase in Chronic and Lifestyle-Related Diseases
One of the major factors driving the growth of the biopharma clinical trials market is the increase in prevalence of chronic and lifestyle-related diseases, such as cancer, diabetes, heart conditions, and neurological disorders, which require the development of targeted therapies. This drives the need for clinical trials to test these treatments, often involving specialized trials to evaluate safety and effectiveness. The integration of AI, machine learning, and real-world evidence is transforming how clinical trials are designed, patients are recruited, and data are analyzed, thereby accelerating drug development. Moreover, government funding and incentives for drug development and clinical studies drive market growth.
Opportunity
Expanding Demand for Cell and Gene Therapies and the Integration of Digital Health
The biopharma clinical trials market is poised for significant growth driven by the increasing demand for cell and gene therapies (CGT), particularly in the treatment of rare and genetic diseases. These advanced therapies offer promising, potentially curative solutions where conventional treatments fall short. Innovations such as CRISPR and other gene editing technologies are accelerating the development of highly targeted therapies, reshaping the clinical research landscape. Strategic collaborations among biopharma companies, contract research organizations (CROs), and academic institutions are fostering innovation through shared expertise and resources. Additionally, the growing adoption of digital health tools—such as wearable devices and electronic health records (EHRs)—is improving patient monitoring, data collection, and trial efficiency, further strengthening the market outlook.
Recent Developments
- In April 2025, Axtria Inc. launched LUCCID (LLM-based Unstructured Clinical Concept Identification), an AI-powered solution that enhances how clinical researchers extract and process unstructured data from electronic health records (EHRs). LUCCID transforms unstructured data into structured formats, addressing the bottleneck in clinical trials caused by manual data extraction, ensuring efficiency and accuracy in data abstraction.
- In June 2024, IQVIA introduced One Home for Sites, a clinical trial technology platform designed to streamline trial management through a single sign-on and dashboard for multiple tasks. This solution addresses technology overload at research sites, enhancing operations and allowing for improved patient focus and trial management. The platform was developed based on insights from over 100 site personnel and is currently being piloted at Prime Sites of IQVIA.
- In February 2025, Selkirk Pharma, Inc. announced the launch of ClinFAST™, a service aimed at accelerating the fill/finish process for clinical trial supplies. This service addresses a major challenge for biotech and pharmaceutical companies, which often face delays in securing capacity from larger contract manufacturers. The launch emphasized the importance of timely production, stating that ClinFAST enables clients to maintain high-quality standards without lengthy wait times.
Biopharma Clinical Trials Market Top Companies
- IQVIA
- ICON plc
- Labcorp Drug Development (Covance)
- Syneos Health
- Parexel International
- Medpace
- PPD (part of Thermo Fisher Scientific)
- Charles River Laboratories
- Wuxi AppTec
- KCR
- PRA Health Sciences (acquired by ICON)
- Clinipace (merged with dMed)
- PSI CRO
- Novotech
- CTI Clinical Trial & Consulting
- Veristat
- Covar Pharmaceuticals
- BioAgile Therapeutics
- Advanced Clinical
- Fortrea
